Fig. 1From: Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusGlucose reabsorption by the normal kidney, showing the site of action of sodium-glucose cotransporter (SGLT) 2 inhibitors. Modified with permission from Chao and Henry [7]Back to article page